Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation ...
Quarterly net revenues were RMB1,000.5million (US$143.1 million)1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results